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Summary A previous publication (Leith et al., 1992) showed that administration of basic fibroblast growth
factor (FGF-2, 0.25 mg kg-', q.i.d. x 7) to mice bearing xenografted DLD-2 human colon cancers would
increase treated tumour growth rates as compared to control neoplasms. Additionally, at the end of the 7 day
treatment period, clonogenic excision assays showed that the percentage of hypoxic cells in tumours from mice
receiving FGF-2 administration was significantly decreased as compared to control neoplasms (from about 42
to about 19%). The present study was undertaken to better define the kinetics of changes in hypoxic
percentages as a function of tumour volume and FGF-2 treatment. In sham-injected control tumours, the
hypoxic percentage increased from about 14% at day 15 postimplantation, (i.e. when sham- or FGF-2
injections were begun) to about 42% by day 22, and to about 75% at 29 days postimplantation (respective
average volumes 220, 910, and 2810 mm3). In contrast, the hypoxic percentages in mice treated with FGF-2
remained at the levels seen in control mice on day 15, not only throughout the 7 day FGF-2 treatment
schedule, but for at least 1 week after the cessation of growth factor administration. The hypoxic percentage
was 16% on day 29 postimplantation, even though everage tumour volumes were about 4325 mm3. These data
show that the effect of FGF-2 administration on tumour growth rate and hypoxic percentages in xenografted
DLD-2 neoplasms is rapid, and continues for some period of time even after administration is ended. Studies
of tumour perfusion with injected 86RbCl at equivalent tumour volumes of about 1800 mm3 indicated that the
percentage of cardiac output to FGF-2 treated tumours was 33% greater than in sham-injected control
neoplasms.
We recently reported in this journal that administration of
basic fibroblast growth factor (FGF-2; q.i.d. x 7; 0.25 mg
kg-') caused a significant increase in the growth rates of
xenografted DLD-2 human colon cancers, and concomitantly
decreased the percentage of hypoxia within these neoplasms
(Leith et al., 1992). In that study, hypoxia levels were deter-
mined 1 day after the end of a 7 day period of FGF-2
administration, at a time when the volumes of control (given
sham-injections with Hank's balanced salt solution) or FGF-
2 treated tumours had increased from 211 mm3 to 992 and
1751 mm3 respectively. Although the FGF-2 treated tumours
were about 1.8 times the volume of controls at the time of
assay, the percentage of hypoxia within these neoplasm was
19.1% (13.5-26.9; 95% confidence limits) whereas the
percentage in control neoplasms was 42.2% (34.2-52.1). In
essence, increases in tumour volume can be uncoupled from
changes in hypoxia by FGF-2 administration. In these
studies however, the effects of the nonequivalent tumour
volumes on interpretation of steady-state levels of hypoxia as
a function of volume were not explicitly studied.
Because of our lack of knowledge of how steady-state
levels of hypoxia within unperturbed DLD-2 tumours might
change as a function of volume, we performed further
experiments to define these kinetics. Additionally, we
examined hypoxia levels in FGF-2 treated DLD-2 tumours at
several times during and after the administration of growth
factor.
Materials and methods
Cell line
The biological characteristics of the DLD-2 cell line have
been previously described (Leith et al., 1992). For these
experiments, stock cells stored in liquid nitrogen were grown
in RPMI-1640 medium containing 10% foetal bovine serum
(FBS), 1% sodium bicarbonate, 1% anti-PPLO reagent, 1%
4-(2-hydroxyethyl)- 1-piperazineethanesulfonic acid buffer,
and 0.04% gentamicin (all reagents from the Grand Island
Biological Co., Grand, Island, NY).
Mice andproduction ofxenografted tumours
Young adult male mice were obtained from the Charles
River Breeding Laboratories, North Wilmington, MA. Mice
were housed, five per large cage, with dust covers, in a
dedicated room in the Brown University Animal Care
Facilities in a laminar flow hood (Thoren Industries, King of
Prussia, PA). Mice were quarantined for 1 week, and were
ear tagged for identification. To produce tumours (one
tumour per animal), DLD-2 cells were trypsinised (0.05%
trypsin, 0.54 mM EDTA) from exponentially growing cul-
tures, and resuspended as single cells in Hank's basic salt
solution (HBSS) at a concentration of 5 x 107 cells ml-'.
Nought point two ml of the cell suspension was injected into
the right flank regions of the mice.
Volumetric procedures
Tumours were measured in two orthogonal diameters and
volumes (mm3) were calculated using the formula for a pro-
late ellipsoid [V (mm3) = L x W2/2] where L and W are
respectively the major and minor diameters (Leith et al.,
1992). All measurements were made by a single individual.
After injection, tumours were monitored until average sizes
of 220 mm3 were reached, at which time animals were ran-
domly assigned to control or FGF-2 groups. The tumour
sizes in this work are comparable to those used in our
previous study on the effects of FGF-2 (Leigh et al., 1992).
Treatment ofnude mice bearing DLD-2 xenografts with FGF-2
Recombinant human FGF-2 (purity>98%) obtained from
Bachem Bioscience, Inc., Philadelphia, PA was used. FGF-2
was reconstituted from lyophilised powder using HBSS, and
was stored for short periods of time at - 20°C in HBSS at a
concentration of 1 ytg -'. The endotoxin level as noted by
the company was less than 0.1 ngpg-` of FGF-2. FGF-2 was
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administered i.p. at a dose of 0.25 mg kg-' day-' for a
period of 7 days, in keeping with our previously published
protocol (Leith et al., 1992). Sham injections were done using
HBSS.
Determination ofhypoxicfractions ofxenografted DLD-2
tumours
Tumours were irradiated in either air-breathing, unanaes-
thetised mice or mice that had been asphyxiated by a 10 min
exposure to nitrogen gas prior to irradition (Leith et al.,
1992). For irradiations, mice were briefly anesthaetised with
Metofane (methoxyflurane; Pitman-Moore, Inc., Washington
Crossing, NJ) and restrained on a lucite irradiation platform.
Animals were allowed to fully recover from the anaesthesia,
and were then irradiated at room temperature using a Philips
250 kVp X-ray machine (Philips X-Ray, New Bedford, MA),
operated at 250 kV and 15 mA. Exposure doses were
measured using a Victoreen R-meter (Victoreen Co., Cleve-
land, OH), and absorbed doses were calculated using appro-
priate temperature, pressure, and Roentgen to Gy conversion
factors. The absorbed dose rate was about 1 Gy min-'.
For determinations of clonogenic cell survival by excision
assay, we delivered graded doses of 0-25 Gy to oxic and
hypoxic tumours in either control or FGF-2 treated mice.
Immediately after irradiations, neoplasms were excised under
sterile conditions, quartered, placed into ice-cold HBSS, and
weighed. Then the pieces were minced using opposed scalpel
blades into approximately 1 mm3 fragments, and placed into
an enzyme cocktail containing 0.2% RNase free DNase
(Sigma Chemical Co., St. Louis, MO), 0.25% collagenase
(Boehringer Mannheim Biochemicals, Indianapolis, IN), and
0.25% neutral pronase (Calbiochem Corp., San Diego, CA)
in RPMI- 1640 medium without FBS. Tumour fragments
were digested for 40 min at 37°C in stirred 250 ml trypsinis-
ing flasks. The digestate was filtered through an 80OtM rectan-
gular stainless steel mesh and pelleted (after addition of an
equal volume of cold RPMI-1640 medium with FBS) at
1,000 r.p.m. for 10 min at 4°C. The pellet was resuspended in
RPMI-1640 medium with FBS, tumour cells were counted
using phase contrast microscopy, and appropriate numbers
of cells were then seeded into 60 or 100 mm diameter plastic
dishes (B-D Labware, Trenton, NJ) at several dilutions for
enumeration of survival by colony formation. Heavily
irradiated (30 Gy, 137CS gamma-rays; Model 68A irradiator,
J.L. Sheperd Co., Glendale, CA) DLD-2 feeder cells were
added to all dishes to keep a minimum cell number of 105
cells/60 mm dish because the colony forming efficiency of
DLD-2 cells is feeder cell dependent (Leith et al., 1992).
Colonies were allowed to develop at 37°C in a humidified
incubator under an atmosphere of 5% CO2 and 95% air for
10- 14 days, after which time colonies were fixed and stained
with 0.5% crystal violet in absolute methanol. To calculate
hypoxic percentages at each dose point (5, 10, 15, 20, and
25 Gy) for oxic or hypoxic control of FGF-2 tumours, we
first calculated the mean survival values from the 4-6 mice
used in each determination of survival. The average survival
values for oxic or hypoxic curves were then fit using linear
regression analysis of log survival vs dose to determine the
slopes of the curves and their 95% confidence limits (Gold-
stein, 1964). The regression equations were statistically com-
pared to determine that the respective oxic and survival
curves were parallel over the 5-25 Gy dose range (i.e., that
the 95% confidence limits on estimations on the slopes of the
curves overlapped). At each dose point (5-25 Gy), the
hypoxic fraction (HF) was then calculated using the relation-
ship
Log (HF) = log (S.)-log (Sh)
where S. and Sh represent that respective mean survival
values of cells from oxic and hypoxic tumours respectively.
Therefore, five estimations of the HF were obtained from
each comparison for each condition (i.e. control tumours,
FGF-2 treated tumours, size/time dependence). The hypoxia
value cited for each condition is the log mean of these five
estimations, with the 95% confidence limits given by the log
s.e.m. determined for each log mean times the two-tailed
t-value appropriate for the sample number with (N-2) degrees
of freedom (Goldstein, 1964).
Estimates of tumour perfusion
In these studies, 0.1 ml (25 pCi) of "6RbCl in 0.9% saline
(specific activity 1-12 mCi mg-'; Amersham Radiochemicals,
Arlington Heights, IL) was injected into the tail veins of
unanaesthetised tumour bearing mice (Sapirstein, 1958). The
percentage uptake of86RB corresponds to the distribution of
cardiac output. Mice were sacrificed by cervical dislocation
after 2 min, and tumours were immediately excised, blotted,
and placed into pre-weighed counting tubes. The tails of the
mcie were also removed and counted to insure that the
residual activity at the site of injection was less than 10%
that of the injected solution. The radioactivity of the samples
was determined using a Beckman Model G-1000 gamma-
counter (Beckman Instruments, Palo Alto, CA), and are
expressed as percent of activity injected g' wet weight of
tumour. Tumours were dried at 100°C for 24 h to insure that
the FGF-2 treatment had not altered the water content of
neoplasms (Lin & Song, 1990). There were 12 mice in both
the FGF-2 and sham-injected control groups.
In these perfusion studies, FGF-2 treated or control
tumours were compared at equivalent volumes. FGF-2
treated tumours were studied 1 day after the end of the 7 day
administration schedule (day 22 postimplantation) when
average tumour volumes were 1748 mm3 (s.e.m. 244.6 mm3).
HBSS injected tumours were allowed to grow to the same
average volume (1882 mm3, s.e.m. 220.1 mm3) as FGF-2
treated neoplasms, which occurred on day 26 post-implan-
tation.
Results
As we noted in our previous work (Leith et al., 1992),
administration of FGF-2 at a rate of 0.25mgkg-' day-'
over the 7 day administration period did not produce altera-
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Figure 1 Volumetric growth of xenografted human DLD-2
tumours in nude mice. Data are shown for tumour growth in
animals receiving i.p. injections (q.i.d. x 7) of basic fibroblast
growth factor (bFGF) (0, 0.25 mg kg-' day-'), or Hank's basic
salt solution (0, control). The time during which HBSS or bFGF
injections were given is indicated by the box. The vertial lines in
the Figure indicate the times at which excision assays were per-
formed for determinations of hypoxic percentages. The dashed
line represents the predicted growth rate of tumours after cessa-
tion of bFGF administration if tumours were to immediately
resume growth rates as seen in control neoplasms of similar size.
s.e.m.s are not shown for purposes of clarity, but were typically
- 15-20% of the mean tumour volume values.
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tions of animal weight or indications of systemic toxicity.
The LD50/30 for FGF-2 in this protocol is about 0.6 mg kg-'
day-'.
In Figure 1, the volumetric growth curves for control or
FGF-2 treated tumours as a function of time after transplan-
tation are shown. Similar to what we have previously
reported, FGF-2 administration results in an increased
growth rate. Tumours reached average volumes of 100mm3
at about 11.5 days after injection. Treatment with HBSS or
FGF-2 was started on day 15 post injection, when average
tumour volumes were 222.4 mm3, and daily treatments con-
tinued for 7 days (days 15-21). Over this time period, the
volumes of control tumours increased to 808.6 mm3 while the
volumes of the FGF-2 treated tumours increased to
1309.8 mm3. Therefore, the volumes of FGF-2 treated neop-
lasms were about 60% greater than that of controls when
FGF-2 treatment was stopped. Volumetric measurements in
control or FGF-2 treated mice were continued beyond the
end of the FGF-2 treatment period (days 22, 25, and 29). In
Figure 1, we have indicated by the dashed line the volumetric
path that the FGF-2 tumours would have been predicted to
follow if they reverted instantly to the growth rates seen in
control neoplasms of the same size. While the experimental
data lie above the dashed line suggesting that there may be
long term effects of the previous FGF-2 administration on
tumour growth, the sizes of the errors on the individual data
points do not allow this to be stated with significance.
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In Figure 2, we present the clonogenic x-ray survival
curves for cells from control or FGF-2 treated tumours as a
function of volume. As there were no situations in which
parallelism was not demonstrated, this then allowed us to
determine the hypoxic fraction. In panel a, data for control
neoplasms are shown. As tumours grow larger, the estimated
hypoxic fractions also increase. In panel b, the data from the
FGF-2 treated mice are shown. In these clonogenic assay
studies, we thought it necessary to perform survival curve
determinations on both oxic and hypoxic tumour cells from
control or FGF-2 treated tumours at all assay times
(volumes), because FGF-2 can act as a radioprotective agent
(Haimovitz-Friedman et al., 1991). If radioprotection were to
occur during these experiments, the result might have been to
alter cell survival as determined from these clonogenic
excision assays, and shift the relative vertical positions of the
oxic and hypoxic survival curves from which hypoxic frac-
tions were determined.
The cell yields from control of FGF-2 treated DLD-2
tumours were not significantly different at early times during
the excision assays. There was however, a decrease in cell
yields seen in the control tumours at the larger sizes (i.e., at
30 days posttransplantation). These data are summarised in
Table I.
In Figure 3, we show a plot of the hypoxic percentages
seen in the control and FGF-2 treated tumours as a function
of volume. Several points are of interest. First, the hypoxic
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Figure 2 Survival of DLD-2 cells from solid tumours after graded dose x-irradiation. In panel a, survival is shown for cells from
control tumours excised from air-breathing, unanaesthetised mice at 15 (0), 17 (0), 19 (A), 22 (A), 25 (0), or 29 (-) days
postimplantation. Each curve has been fit using a best-fit, least square linear regression of (log) percent hypoxia vs dose. Because
the survival responses of cells taken from completely hypoxic tumours did not change as a function of time postimplantation, these
data are represented by a single curve (O). In panel b, similar data are shown for hypoxic or oxic cells excised from tumours given
daily i.p. doses (q.i.d. x 7) of basic fibroblast growth factor (bFGF, 0.25 mg kg-', day-', days 15-21 postimplantation) (symbols:
day 15 = 0 (repeated from panel a); day 17 = 0; day 19 = A; day 22 = A, day 25 = 0; day 29 = U). As there were no significant
changes in the survival of either oxic or hypoxic cells from animals treated with bFGF as a function of time, a single line has been
fit to these data, as indicated by the solid lines. For purposes of comparison, the dashed lines in panel b represent the survival of
oxic or hypoxic control (non-bFGF treated) tumour cells (15 days postimplantation) as shown in panel a. There were 4-6
determinations per dose point for all conditions shown in panels a and b. There was no dependence on the s.e.m.s of the mean
survival points shown in panels a and b on tumour volume at a given dose. s.e.m.s as a log percentage of the log mean survival
values did however increase from 4.4% to 5.8, 15.7, 34.0, and 42.7% at doses of 5, 10, 15, 20, and 25 Gy respectively.730 J.T. LEITH & S. MICHELSON
Table I Cell yields (CYs) and colony forming efficiencies (CFEs) of control or FGF-2 treated
human colon tumour xenografts as a function of time after implantation
Days after implantation
15 17 19 22 25 29
Controls
Cya 4.62 (0.33) 5.09 (0.41) 3.98 (0.29) 4.43 (0.33) 3.72 (0.22) 2.76 (0.40)
CFEb 6.01 (0.20) 4.87 (0.38) 6.10 (0.71) 7.32 (0.37) 3.51 (0.29) 3.02 (0.68)
FGF-2C
CY 6.01 (0.51) 5.32 (0.19) 4.76 (0.34) 3.50 (0.50) 4.19 (0.36) 3.48 (0.29)
CFE 5.30 (0.91) 6.99 (0.38) 4.81 (0.89) 7.15 (1.02) 4.00 (0.54) 4.26 (0.55)
aCellsmg' x 104: mean and s.e.m. bColony forming efficiency: mean and s.e.m. CFGF-2
administered daily from days 15 to 21 at a dose of 0.25mgkg-'.
99q . I,, I,, 11
95
90
0.
c
a)
a)
a.
70
50
30
10
5
102 103
Tumour volume (mm3)
104
Figure 3 Changes in the percentage of hypoxia within tumours
from either control (0) or basic fibroblast growth factor (0)
treated mice as a function of tumour volume. The dashed line
represents the predicted increase in intratumour hypoxia after
cessation of bFGF administration if the response was similar to
that seen in control neoplasms. The error bars are means and
95% confidence limits.
percentages in the FGF-2 treated mice remain constant at the
value seen at the start of treatment (i.e. about 14%) in
tumours with volumes of about 220 mm3. Second, the effect
is present even within 2 days of FGF-2 treatment. Third,
even after FGF-2 administration is ended, the hypoxic
percentage remains unchanged over the next 7 days (animals
were sacrificed at this point as tumour volumes were becom-
ing large). In the Figure, we have indicated by the dashed
line what might have been observed if the hypoxic percentage
in the tumours of the FGF-2 treated mice immediately began
to increase at a rate similar to that seen in the control mice
at the end of treatment. The dashed line predicts that the
hypoxic percentage would have increased to about 30% in
that 7 day period, rather than remain at the observed level of
19%.
These results also show that FGF-2 has not altered the
positions of the hypoxic survival curves determined from
control or FGF-2 treated tumours as a function of tumour
size or treatment time, and suggest that FGF-2 is not acting
as a radioprotective agent.
The uptake of 86Rb in the FGF-2 or sham-injected
tumours (%/g wet weight) was respectively 5.42 (0.75) and
4.09 (0.51) (values in parentheses are the 95% confidence
limits), a difference which is significant at the 5% level of
confidence (Goldstein, 1964). No significant change in
tumour water content was caused by the FGF-2 injections as
indicated by comparison of the weights of the 100°C dried
samples.
Discussion
The primary results of this study are, first, that hypoxic
fractions increase significantly with volume in unperturbed
DLD-2 neoplasms. This result is consistent with findings in
other model tumour systems as summarised by Moulder &
Rockwell (1984), and Rockwell & Moulder (1990). Second,
FGF-2 administration prevents the steady increase in the
percentage of hypoxia seen in DLD-2 control neoplasms of
increasing size. Hypoxic percentages in FGF-2 treated DLD-
2 human colon cancers remain at levels of 14-18%, while
the levels in control neoplasms increase from 14 to about
42% over the same time period. This result is obtained even
in the face of the fact that the FGF-2 treated neoplasms
actually have larger volumes at the end of growth factor
administration than do controls. Third, this inhibitory effect
on hypoxia expression continues for at least 1 week after
cessation of FGF-2 administration.
Relevant to the above, Gross et al. (1993), who have also
studied the effects of exogenously administered FGF-2 on
DLD-2 tumour growth, showed that DLD-2 cells lack high
affinity receptors for FGF-2, and produce low levels of
immunoreactive FGF-2 (about 3 ng 10-6 cells). Autoradio-
graphic sections prepared from DLD-2 tumours in animals
given ['251I]rHu-FGF-2 showed that the binding was to
endothelial cells, not to parenchymal tumour cells. Gross et
al. (1993) therefore explain the observed increases in the mass
of FGF-2 treated DLD-2 tumours as a result of increased
angio-genesis/mitogenesis of tumour endothelial cells.
Although Gross et al. (1993) did not examine the binding of
FGF-2 to endothelial cells in conjunction with time depen-
dent changes in endothelial cell proliferation, Gospodarowicz
et al. (1976) have shown that the proliferative response of
cultured endothelial cells to increased levels of FGF-2 is
essentially instantaneous. This would be consistent with the
rapid increase in tumour volume, and inhibition of increases
in intratumour hypoxia. Our finding that hypoxic percen-
tages remain low for some time after cessation of FGF-2
administration would be consistent with a sustained FGF-2
induced increase in overall vascular capability, which may be
due to FGF-2 binding by the tumour extracellular matrix
during administration (e.g. heparan sulfate proteoglycans),
with subsequent gradual release of bound FGF-2 by heparin-
ase and other proteolytic enzymes (Flaumenhaft et al., 1989,
1990; Folkman et al., 1988; Vlodavsky et al., 1991). It is
fortuitous that, in our choice of DLD-2 neoplasms to study
FGF-2 related changes in intratumour hypoxia, DLD-2 cells
contain low levels of FGF-2. Consequently, the background
paracrine FGF-2 signal from tumour cells (D'Amore, 1990)
to endothelial cells would be low, producing a situation
where demonstration of a tumour response to exogenously
administered FGF-2 would be optimal. Conversely, the pos-
sibility arises that, for tumours in which parenchymal cells
produce high levels of FGF-2, the vasculature might already
be supplied with high levels of endogenous FGF-2, and
therefore exogenous administration of FGF-2 would have no
effect. Support for this is given by Gross et al. (1993), who
found that administration of FGF-2 to rat C6 solid tumours
had no effect on tumour size. However, C6 cells produce
about 630% more immunoreactive FGF-2 per cell than do
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DLD-2 cells. These results also raise the possibility that
absolute levels of FGF-2 production by various tumour cells
might be correlated, probably in an inverse manner, to
steady-state levels of hypoxia. The results presented herein on
the 33% increase in tumour perfusion as measured by 86RbCl
uptake, taken together with the studies of Gross et al. (1993)
identify the tumour vasculature as the target for FGF-2
induced changes in growth and hypoxia in this model tumour
system. Still, as noted by Lin and Song (1990), our 86Rb
measurements only indicate the percentage of cardiac output
distributed to the tumour, and may not necessarily indicate a
real change in tumour blood flow in mlmin-'. Additional
studies on blood flow (e.g. with laser Doppler flowmetry)
would be useful.
Our results suggest that administration of growth factors
such as FGF-2 during the course of fractionated radio-
therapy might serve to increase the curability of certain solid
tumours if hypoxia is a major problem in curability (e.g.
Gatenby et al., 1988). Several other factors should be con-
sidered in this regard however. For example, Haimovitz-
Friedman et al. (1991) have shown that FGF-2 acts as a
radiation protector for bovine endothelial cells in vitro, in-
creasing cell survival by increasing the recovery from radia-
tion damage. While these results were obtained on normal
tissue, one must consider whether tumour cells would be
similarly protected. In vitro, addition of FGF-2 (up to
0.2tLg ml-') did not alter the shape of the graded dose x-ray
survival curve for DLD-2 cells in either immediate or delayed
plating experiments (J. Leigh, unpublished data, 1992). This
lack of modification of radiation survival by FGF-2 is consis-
tent with the observation of Gross et al. (1993) that DLD-2
cells lack high affinity receptors for FGF-2. Also, Rofstad
(1992) has shown that, if reoxygenation is rapid and exten-
sive during fractionated radiotherapy, overall tumour re-
sponse may not be significantly influenced by hypoxia per se.
Rofstad suggests that intrinsic radiation sensitivity and the
rate of repopulation between radiation fractions may be the
main factors governing overall radioresponsiveness. Given
that our studies show that FGF-2 significantly alters tumour
growth rates, comparative in vivo studies on FGF-2 effects on
repopulation rates in tumours with and without high affinity
receptors for FGF-2 would be of interest.
This work was supported by Grants from the National Cancer
Institute of the National Institutes of Health (CA 50350-04 and 5
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